Can a common diabetes pill block a side effect of another?

NCT ID NCT07053319

Recruiting now Knowledge-focused Sponsor: The University of Texas Health Science Center at San Antonio Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This early study looks at how two diabetes drugs, empagliflozin and pioglitazone, interact in the body. Researchers want to see if pioglitazone can reduce the ketones (a type of acid) that empagliflozin sometimes produces. The study involves 64 adults with type 2 diabetes and measures glucose and ketone levels after taking the drugs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Empagliflozin and Pioglitazone
What this could lead to: If it works, this could help doctors understand how to better combine diabetes drugs to avoid side effects like high ketones.
What could go wrong: This is a very early, small study (Phase 1, 64 people) looking at body chemistry, not at long-term outcomes. Results may not lead to any change in treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Locations

Texas Diabetes Institute/UH
RECRUITING

San Antonio, Texas, 78229-3900, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.